LENZ Therapeutics’ (LENZ) “Buy” Rating Reiterated at HC Wainwright

LENZ Therapeutics (NASDAQ:LENZ)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $38.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 16.92% from the company’s current price.

A number of other research firms have also commented on LENZ. Raymond James assumed coverage on shares of LENZ Therapeutics in a research report on Friday, September 27th. They issued an “outperform” rating and a $37.00 price objective for the company. William Blair raised shares of LENZ Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $36.00 target price on shares of LENZ Therapeutics in a research note on Thursday, August 15th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $35.40.

LENZ Therapeutics Stock Performance

NASDAQ LENZ traded up $0.27 during trading hours on Thursday, reaching $32.50. 264,169 shares of the company were exchanged, compared to its average volume of 135,853. LENZ Therapeutics has a 1 year low of $14.07 and a 1 year high of $36.50. The business’s 50 day simple moving average is $24.49 and its 200-day simple moving average is $20.99.

LENZ Therapeutics (NASDAQ:LENZ) last issued its earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.09. On average, research analysts predict that LENZ Therapeutics will post -3.15 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. American International Group Inc. purchased a new position in shares of LENZ Therapeutics in the first quarter worth $44,000. SG Americas Securities LLC bought a new stake in LENZ Therapeutics in the third quarter valued at $107,000. GSA Capital Partners LLP bought a new stake in LENZ Therapeutics in the third quarter valued at $246,000. Squarepoint Ops LLC bought a new stake in LENZ Therapeutics in the second quarter valued at $181,000. Finally, BNP Paribas Financial Markets bought a new stake in LENZ Therapeutics in the first quarter valued at $362,000. 54.32% of the stock is owned by hedge funds and other institutional investors.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.